Dynavax Technologies Corp (DVAX)

[staccani]

DVAX main point is not about HBV, but is about cancer. TLR9 agonist in combination with anti pd1 (ph1 melanoma naive patients had 100% response to the combo with anti pd1) is probably going to change the Standard of care in many cancers , including NSCLC, for which the convenient aereosol delivery system is going to make the difference compared to IDRA for instance.
Potentially the TLR9 agonist plus anti pd1 combo could become frontline standard therapy in most cancers, starting from the most immunogenic or more accessible like melanoma, NSCLC, head and neck and RCC